Amicus Therapeutics and Blackstone Enter Into $430 Million Strategic Financing Collaboration
October 03, 2023
October 03, 2023
PRINCETON, New Jersey, Oct. 3 (TNSres) -- Blackstone, an investment firm, issued the following news release on Oct. 2, 2023:
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE: BX). As part of the collaboration, Blackston . . .
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone (NYSE: BX). As part of the collaboration, Blackston . . .